CDKN2A and mucinous neoplasm: A minority of mucinous tumors does not display KRAS or BRAF oncogenic mutations; in these tumors, alternative mechanisms drive constitutive RAS signaling, such as RRAS2 mutation, HER2 amplification, ARID1A truncating mutation or ELF3 mutation plus homozygous CDKN2A loss [115].